To date, several factors have been reported in recurrent miscarriage. Genetic mutations are the most important causative factors in women. Fetal thrombotic vasculopathy is a new described placental alteration with varying degrees of involvement and often associated with adverse prenatal outcomes. The diagnosis is made histologically and so is postnatal, which makes it a challenge in clinical practice. The aim of the present study is investigation of the common mutations in women with recurrent miscarriage. Materials and Methods: A cross-sectional study was conducted on 100 women with a history of recurrent miscarriage fetus in 2018. In these patients, several genes such as MTHFR, F2, F5 Leiden, PAI1, F13 and FGB were analyzed by sequencing techniques. The most common mutations in these genes were sequenced and analyzed. Results: According to statistical results obtained, MTHFR gene (C677T, A1298C) has the highest rate (50 %) of common mutations (p=0.001). After that F2 (G20210A) and F5 Leiden (G1691A) have the highest statistical values (each one 20%). In addition to these genes, there are other unknown mutations which have not been studied in terms of pathogenicity. Other genes have a smaller percentage of aborted fetus infrequently. Conclusions: Common polymorphisms in the thrombophilic system are likely to result in abortion in these subjects, due to impaired coagulation of the mother and the fetus. Investigating the presence of common mutations and examining their association with other mutations in the thrombophilia as a prognostic in patients with recurrent miscarriage is necessary.
Introduction
Thrombophilia is an abnormality of blood coagulation which can raise the risk of thrombosis (blood clots in blood vessels) [1] .
Such abnormalities can be identified in 50% of people who have an episode of thrombosis (such as deep vein thrombosis in the leg) not provoked by other causes [2] . Fibrinogen, the precursor of fibrin and the end-product of blood coagulation, is an essential component of the hemostatic system [3] . Fibrinogen is converted to fibrin through limited proteolysis by thrombin which exposes polymerization sites to fibrin monomers [4] . Activated factor XIII forms covalent bonds between adjacent fibrin monomers. These cross-links strengthen the fibrin clot and increase its resistance to degradation by the fibrinolysis system [5] .
There is no specific treatment for the thrombophilias, but recurrent episodes of thrombosis may be an indication for long term preventative anticoagulation [6] . The most common types of congenital thrombo-philia are those that arise as a result of overactivity of coagulation factors. They are relatively mild and are therefore classified as (type 2) defects [7] . The most common types are factor 5 Leiden (a mutation in the F5 at position 1691) and prothrombin G20210A, a mutation in prothrombin (at position 20210 in the 3' untranslated region of the gene).
Thromboembolic events occur as a result of disruption of the balance between fibrinolysis and thrombosis. Thus, it is important to examine the inherited and acquired thrombotic risk factors [8] . In the last five decades, the molecular biases of both coagulation and anticoagulation pathways have been well studied and some hereditary risk factors have been found responsible for venous thromboembolism (VTE) [9] . F5 Leiden (FVL), Prothrombin gene (PT) and methylenetetrahydrofolate (MTHFR) polymorphism are the common molecular biomarkers used in the evaluation of tendency to venous thromboembolism [10] . The mutant F5 molecule is known as F5L and named as F5(R 506 Q) [11] . A single G allele was found as a nucleotide transition at position 20210 in the 3' untranslated region of the prothrombin gene in 18% of selected patients with familial venous thrombosis [12] .
MTHFR enzyme plays a significant role in the cellular metabolism of folate and synthesis of nucleotides and is essential in the methyl cycle that converts homocysteine to methionine [13] . To date, two important MTHFR polymorphisms (C677T and A1298C) have been identified. These polymorphisms are related to reducing MTHFR activity [14] . The C677T mutation is known as a point mutation with the substitution of cysteine-thymine at the nucleotide position 677 of the MTHFR gene. [15] . The adequate fetomaternal circulating system is essential for normal development and function of the placenta [16] . It is obtained with a mechanism which prevents coagulation of the maternal blood around chorionic villas and fetal blood in them.
Normal pathway in coagulation cascade includes the balance between procoagulants, anticoagulant and fibrinolytic components in the blood [17] . Depending on of the type of inherited thrombophilia, there is impaired neutralization of thrombin or failure to control the generation of thrombin. This will cause malfunction of natural anticoagulants that maintain the fluidity of the blood [18] .
Coagulation factor (FV) is a large glycoprotein that is produced in the liver and circulates in plasma as a single-chain inactive precursor.
After limited proteolysis by thrombin or FXa, FV is converted to its active form (FVa), which acts as an essential non-enzymatic cofactor of FXain prothrombin activation [19] .
FVa is inactivated by activated protein C (APC)
via proteolytic cleavage at Arg306, Arg506, and Arg679. Although Arg506 is the kinetically preferred APC-cleavage site, cleavage atArg306 is required for complete loss of cofactor activity. Therefore, FVa is mainly inactivated via initial cleavage at Arg506 which yields an intermediate 40% activity followed by slow cleavage at Arg306 [20] . However, FVa can also be inactivated by a single slow cleavage at Arg306 [21] .
Recurrent miscarriage is a significant clinical problem of different etiologies [21] . Certain thrombophilic gene mutations have been associated with an increased risk of recurrent miscarriage [22] . Also mutations in Folate- 
Polymerase chain reaction and Sequencing
Primers for polymerase chain reaction (PCR) were designed by Gene Runner software (version 3.05) and their specificity for PCR was checked by nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) [25] .
After DNA extraction, the PCR was performed with specific primer (Table 1) Moreover, many homozygous mutations in this gene were observed. In the following, common heterozygous mutations in these genes are visible ( Table 2 and Fig. 1 ). In addition, the percentages of heterozygote and homozygote for mutations in MTHFR, F2 and F5 Leiden, being the most frequent among the studied subjects, are illustrated in table 3. A and B both belong to the results of sequence of the gene MTHFR by reverse primers, which indicate the conversion of A>C and C>T respectively .In both cases, the mutant is heterozygous. In figure C, a mutation in the F2 gene is shown which is marked with a flash of heterozygote mutation. The type of mutation in figure D identified belongs to F5 gene. This mutation is homozygous and G>A. Moreover, E and F respectively belong to the results of sequence of the gene PAI and F13, which indicate the heterozygous mutant.
Discussion
The development of venous thrombosis is generally considered to involve in a combination of locoal regional and systemic prothrombogenic factors [23] . Portomesenteric vein thrombosis (PMVT) is an uncommon but potentially catastrophic clinical complication that may lead to intestinal ischemia and infarction [26] Furthermore, it was reported that the double heterozygotes had thrombosis at a significantly younger age compared to the rest [3] . Other than FV Leiden, another mutation F2 19911A>G found in the same gene has also been described as a risk factor which slightly increases the risk of venous thrombosis when co-existing with the F2 (20210G>A) mutation [5] . Rai and colleagues reported that there is no increase in mutation rates in coagulation factor 5 compared with healthy subjects. In this study, the 20% mutation prevalence in the population studied was related to this mutation [29] .
Studies conducted among different racial groups have confirmed varying prevalences of the individuals with F2 20210G>A mutation [8] .The highest prevalence of F2 20210G>A mutation has been reported among Caucasians of European origin and Mediterranean populations living close to Europe [11] .
Furthermore, the prevalence of the mutation in these populations is higher among patients with thromo-embolic disorders compared with healthy controls [26] . However, in many Asian countries it is reported to be absent in both the healthy controls as well as the patients with thrombo-embolic disorders [21] . In 2009, a study was conducted by Dissanayake et al. to determine the F2 20210G>A mutant allele frequency among healthy controls in the Sri Lankan population. They reported that the mutation was absent among healthy controls across all the three ethnic groups (Sinhala, Tamil and Moor) in Sri Lanka [30] . The present study was undertaken to determine the prevalence of the F2, 20210G>A mutation among Sri Lankan patients with thromboembolic disorders [9, 30] . In contrast to most reports from other Asian populations, we found that the mutation was not entirely absent among these patients as 0.8 % were heterozygotes for the mutation with a mutant allele frequency of 0.4 % [28] .
Some of the individual studies have detected an increased risk of pregnancy loss in Indian, Turkish, and the Tunisian population with 1298AC and 1298 CC polymorphisms [31] [32] [33] .
Mean plasma homocysteine was elevated among 1298AA homozygotes as compared with 1298C allele and was associated with recurrent pregnancy loss [34] . MTHFR 1298 AC genotype allele increased the risk of spontaneous abortion along with MTHFR-C677T [35] . In this study, the frequency of MTHFR gene was 50% so that 30% was found in MTHFR (A1298C) and 20% was identified in MTHFR (C677T). Base on our result, this mutation was higher than the other common mutation in thrombophilia.
Conclusion
In this study, the frequency of mutant allele of the gene MTHFR has a slightly higher can be referred to as very important genetic mutagenesis. In relation to MTHFR gene mutagenesis and F2, it can be concluded that these two genes may also be involved in recurrent miscarriage of the fetus.
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